MX351889B - Composiciones y métodos anti-cxcr1. - Google Patents

Composiciones y métodos anti-cxcr1.

Info

Publication number
MX351889B
MX351889B MX2015011045A MX2015011045A MX351889B MX 351889 B MX351889 B MX 351889B MX 2015011045 A MX2015011045 A MX 2015011045A MX 2015011045 A MX2015011045 A MX 2015011045A MX 351889 B MX351889 B MX 351889B
Authority
MX
Mexico
Prior art keywords
cxcr1
methods
tumorigenic
present
compositions
Prior art date
Application number
MX2015011045A
Other languages
English (en)
Inventor
S Wicha Max
Ginestier Christophe
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX351889B publication Critical patent/MX351889B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

La presente invención se refiere a métodos para tratar cáncer mediante la administración de un inhibidor de la senda IL8-CXCR1 (por ej., un anticuerpo anti-CXCR1 o Repertaxin) solo o en combinación con un agente quimioterapéutico adicional de manera tal que se matan las células de cáncer no tumorigénicas y tumorigénicas en un sujeto. La presente invención también proporciona composiciones y métodos para detectar la presencia de y aislar células madre de tumores sólidos en un paciente (por ej., basados en la presencia de CXCR1 o FBXO21).
MX2015011045A 2008-11-11 2011-05-11 Composiciones y métodos anti-cxcr1. MX351889B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11345808P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
MX351889B true MX351889B (es) 2017-11-01

Family

ID=42170302

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011005007A MX2011005007A (es) 2008-11-11 2009-11-11 Composiciones y metodos anti-cxcr1.
MX2015011045A MX351889B (es) 2008-11-11 2011-05-11 Composiciones y métodos anti-cxcr1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011005007A MX2011005007A (es) 2008-11-11 2009-11-11 Composiciones y metodos anti-cxcr1.

Country Status (26)

Country Link
US (3) US8940301B2 (es)
EP (2) EP3153862A1 (es)
JP (3) JP5716180B2 (es)
KR (3) KR20150065930A (es)
CN (3) CN104623664B (es)
AU (1) AU2009314141B2 (es)
BR (1) BRPI0921150B1 (es)
CA (1) CA2743305C (es)
CY (1) CY1118933T1 (es)
DK (1) DK2356462T3 (es)
EA (1) EA023466B1 (es)
ES (1) ES2623128T3 (es)
HK (3) HK1161350A1 (es)
HR (1) HRP20170463T1 (es)
HU (1) HUE032623T2 (es)
IL (1) IL212822A (es)
LT (1) LT2356462T (es)
MX (2) MX2011005007A (es)
NZ (2) NZ625440A (es)
PL (1) PL2356462T3 (es)
PT (1) PT2356462T (es)
RS (1) RS55784B1 (es)
SG (1) SG10201701954QA (es)
SI (1) SI2356462T1 (es)
WO (1) WO2010056753A1 (es)
ZA (1) ZA201103416B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0921150B1 (pt) 2008-11-11 2022-05-10 The Regents Of The University Of Michigan Uso de um antagonista de cxcr1 para o tratamento de tumor
GB201106870D0 (en) * 2011-04-26 2011-06-01 Univ Belfast Marker
ES2697674T3 (es) * 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
EP2831112A1 (en) * 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
CN105339390A (zh) * 2013-04-29 2016-02-17 Ogd2药物 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略
JP6683986B2 (ja) * 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
WO2018067548A1 (en) 2016-10-03 2018-04-12 The Children's Medicial Center Corporation Prevention and treatment of diabetic nephropathy
CA3044030A1 (en) * 2016-11-17 2018-05-24 Nantbio, Inc. Validation of inferred anticancer pathways
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10100275B2 (en) 2017-03-16 2018-10-16 King Faisal Specialist Hospital & Research Centre Method for generating human multipotent mammary stem cells from normal primary breast luminal cells
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
RU2702910C2 (ru) * 2018-12-20 2019-10-14 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения количества стволовых клеток рака молочной железы
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
RU2700695C2 (ru) * 2019-02-27 2019-09-19 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ снижения клоногенной активности стволовых клеток рака молочной железы
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
TW202128213A (zh) * 2020-01-10 2021-08-01 大陸商北京銳瑟生物醫藥科技發展有限公司 一種用於緩解癌症化療引起抗藥性並對化療增效之醫藥組合物及其用途
CN114075286A (zh) * 2020-08-21 2022-02-22 张家港博泽利斯生物技术有限公司 一种抗人cxcr1蛋白单克隆抗体的制备方法
WO2023032957A1 (ja) * 2021-08-30 2023-03-09 学校法人東京薬科大学 がんの予防および／または治療のための医薬組成物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
EP0672131B1 (en) 1992-10-30 2003-12-17 The General Hospital Corporation A novel cell cycle control protein
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6156305A (en) 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE19681033D2 (de) * 1995-11-16 1999-03-18 Michael W Dahm Verfahren zur Quantifizierung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
JP2000502450A (ja) 1995-12-22 2000-02-29 アボツト・ラボラトリーズ 蛍光偏光免疫アッセイによる診断法
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
JP2001509135A (ja) 1996-10-11 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法
WO1998039636A1 (en) 1997-03-07 1998-09-11 Clare Chemical Research Llc Fluorometric detection using visible light
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2002062850A2 (en) * 2001-02-02 2002-08-15 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
JP2005511754A (ja) 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ
US7919083B2 (en) * 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
PT1629088E (pt) * 2003-05-30 2012-04-10 Agensys Inc Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
US20050142136A1 (en) * 2003-10-23 2005-06-30 Lary Suva Anti-interleukin 8 therapy for tumor osteolysis
JP2007526455A (ja) 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
WO2005103711A2 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2005113534A2 (en) 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
GB0417740D0 (en) 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
WO2007053648A2 (en) * 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070208074A1 (en) 2006-01-24 2007-09-06 Bonni Azad M Methods and compositions for treating and preventing tumors
US20090093451A1 (en) 2006-04-21 2009-04-09 Smithkline Beecham Corporation IL-8 Receptor Antagonists
WO2008036419A2 (en) * 2006-09-22 2008-03-27 The Regents Of The University Of Michigan Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker
JP5311439B2 (ja) * 2006-12-27 2013-10-09 日本メナード化粧品株式会社 皮膚の状態を評価する方法及びその用途
CN101126758A (zh) * 2007-09-06 2008-02-20 江苏省肿瘤医院 流式细胞术同步检测肿瘤中多种细胞蛋白表达的方法
WO2010009121A2 (en) * 2008-07-15 2010-01-21 University Of Florida Research Foundation, Inc. Colon stem cells associated with colitis and colorectal cancer and methods of use
BRPI0921150B1 (pt) 2008-11-11 2022-05-10 The Regents Of The University Of Michigan Uso de um antagonista de cxcr1 para o tratamento de tumor

Also Published As

Publication number Publication date
US20150160227A1 (en) 2015-06-11
US20100136031A1 (en) 2010-06-03
IL212822A (en) 2017-05-29
CN104623664A (zh) 2015-05-20
NZ625440A (en) 2016-01-29
ZA201103416B (en) 2012-08-29
BRPI0921150B1 (pt) 2022-05-10
HK1206256A1 (en) 2016-01-08
BRPI0921150A2 (pt) 2020-11-17
KR20110093893A (ko) 2011-08-18
US8940301B2 (en) 2015-01-27
CA2743305A1 (en) 2010-05-20
SG10201701954QA (en) 2017-05-30
SI2356462T1 (sl) 2017-05-31
CY1118933T1 (el) 2018-01-10
AU2009314141A1 (en) 2010-05-20
CN102272599B (zh) 2015-01-14
EA201100779A1 (ru) 2011-12-30
EP2356462B1 (en) 2017-01-04
IL212822A0 (en) 2011-07-31
PL2356462T3 (pl) 2017-07-31
EP3153862A1 (en) 2017-04-12
ES2623128T3 (es) 2017-07-10
US20150094362A1 (en) 2015-04-02
EA023466B1 (ru) 2016-06-30
LT2356462T (lt) 2017-03-10
KR20140132412A (ko) 2014-11-17
AU2009314141B2 (en) 2013-11-07
PT2356462T (pt) 2017-04-07
KR20150065930A (ko) 2015-06-15
MX2011005007A (es) 2011-07-28
EP2356462A1 (en) 2011-08-17
JP2014037427A (ja) 2014-02-27
CN102272599A (zh) 2011-12-07
JP5716180B2 (ja) 2015-05-13
DK2356462T3 (en) 2017-02-27
CA2743305C (en) 2017-04-04
JP5909783B2 (ja) 2016-04-27
EP2356462A4 (en) 2012-09-19
US10557850B2 (en) 2020-02-11
CN104623664B (zh) 2018-08-07
KR101588547B1 (ko) 2016-01-28
JP2012508384A (ja) 2012-04-05
HK1206421A1 (en) 2016-01-08
US9606124B2 (en) 2017-03-28
HUE032623T2 (hu) 2017-10-30
NZ602369A (en) 2015-02-27
HK1161350A1 (en) 2012-08-24
RS55784B1 (sr) 2017-07-31
JP2016065082A (ja) 2016-04-28
HRP20170463T1 (hr) 2017-05-19
CN104634972A (zh) 2015-05-20
WO2010056753A1 (en) 2010-05-20
CN104634972B (zh) 2017-06-13

Similar Documents

Publication Publication Date Title
MX351889B (es) Composiciones y métodos anti-cxcr1.
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
PH12015502362A1 (en) Certain chemical entities, compositions and methods
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
MX355543B (es) Macrociclos peptidomiméticos.
EA201300171A1 (ru) Способы и композиции для терапии рака печени
PH12014501106B1 (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
EA201171367A1 (ru) Винилиндазолильные соединения
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
MX2014006241A (es) Metodos de tratamiento usando un anticuerpo contra interferon gamma.
TR201818814T4 (tr) Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
MA33973B1 (fr) Méthodes de traitement du cancer à l'aide d'antagonistes de notch
WO2012058241A3 (en) Methods and compositions for ameliorating pancreatic cancer
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения